Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease
Recruiting · NCT06006819 · Observational (researchers observe without assigning treatment) · Lead sponsor: Cheng-Hsin General Hospital
View the official record on ClinicalTrials.gov →What this trial is about
Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.
Who can take part
Inclusion criteria
- hospitalized for acute heart failure
Exclusion criteria
- initial serum NT-proBNP level \<300ng/ml, pregnancy, amputated, and end-stage renal disease under regular dialysis
Where it is running
2 locations listed.
- Cheng Hsin General Hospital - Taipei, Baitou District, Taiwan
- Cheng Hsin General Hospital - Taipei, Baitou District, Taiwan